Pfizer (PFE)

Indian markets ended sharply lower, dragged by broad-based profit booking, FPI outflows, and fading optimism over the U.S.-India trade deal.

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.

BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.

A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.

Here are three dividend-paying stocks that warrant closer examination.

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors.

Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.92 per share was 36.1% above analysts’ consensus estimates.

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.

According to a Reuters report, the strike comes in the wake of planned job cuts in the region.

KindlyMD CEO Tim Pickett said the merger allows the company to preserve and expand its mission to combat opioid dependency through alternative medicine while gaining a new engine for shareholder value creation.

The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.